Other Financial Statement Information

12 Months Ended

Dec. 31, 2024

Other Financial Statement Information [Abstract]

3. OTHER FINANCIAL STATEMENT INFORMATION

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following (in thousands):


	December 31,
	2024		2023
Interest income receivable	$	3,773	$	512
Prepaid clinical trial costs		2,228		5,273
Prepaid commercial planning costs		933		789
Prepaid insurance		709		597
Prepaid software costs		660		237
Prepaid professional services fees		659		198
Prepaid medical affairs costs		246		—
Prepaid rent		224		257
Prepaid drug manufacturing costs		21		1,207
Other		913		2,237
Total prepaid expenses and other current assets	$	10,366	$	11,307

Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):


	December 31,
	2024		2023
Accrued payroll	$	6,822	$	3,932
Accrued clinical and drug manufacturing expenses		6,742		2,213
Accrued commercial expenses		689		19
Accrued information technology expenses		455		37
Accrued legal fees		257		59
Related party payable		217		1,926
Other accrued expenses and current liabilities		1,041		563
Total accrued expenses and other current liabilities	$	16,223	$	8,749

Related party payable represents amounts due to Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to manufacturing technology and know-how transfer services performed for atacicept pursuant to the license agreement between the Company and Ares (see Note 9).